Business Wire

WORLD’S MOST ICONIC ROCK BAND, THE ROLLING STONES, SELECTS THUNDER RIDGE NATURE ARENA AS DESTINATION FOR FINAL NORTH AMERICAN PERFORMANCE

Share

Bass Pro Shops Big Cedar Lodge announced today that on July 21 the Ozarks will rock as the ancient hills, valleys and lakes never have when the world’s greatest rock-and-roll band, The Rolling Stones, light up Thunder Ridge Nature Arena for the last performance on their final North American tour.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523211894/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rendering of Thunder Ridge Nature Arena (Graphic: Business Wire)

The concert promises to be one of the most memorable and highly anticipated concert events ever. It is a pairing of the World’s Greatest Rock-and-Roll Band and the most breathtaking and awe-inspiring outdoor amphitheater in all of North America.

The Thunder Ridge concert stop is part of the “Hackney Diamonds Tour ’24” for The Rolling Stones, which includes 20 performances in 16 cities. Tickets will go on sale Friday, May 31, and will be available at ThunderRidgeNatureArena.com.

“We’re honored to host The Rolling Stones at Thunder Ridge Nature Arena and to showcase the amazing beauty of the Ozarks to music fans of all generations,” said Johnny Morris, visionary conservationist and founder of Bass Pro Shops. “The Stones are the most iconic rock-and-roll band ever, and we know they will put on a remarkable show that no one will ever forget! Their appearance will become a part of the history of this beautiful mountain in the Ozarks.”

Thunder Ridge is a world-class destination admired by legends of rock.

Representatives from The Rolling Stones scouted Thunder Ridge by attending the sold-out Garth Brooks concert in September 2022. After attending the show, the advance team reported back that Thunder Ridge was one of the most extraordinary and beautiful event venues they had ever seen.

A legendary night of entertainment began on a fishing trip with two of the leading conservationists of our time.

A partnership between The Rolling Stones, the Ozarks and Johnny Morris is something few would have expected; but, in fact, this is a relationship decades in the making. More than 20 years ago, the Stones renowned keyboard and piano player, Chuck Leavell, joined Johnny Morris to celebrate the opening of a Bass Pro Shops near Chuck’s home in Macon, Georgia. Out of this shared experience, Johnny and Chuck developed a special friendship founded on conservation, a love of the outdoors and a few remarkable shared fishing adventures. And now their adventure continues with a concert unlike anything that has ever been seen in the Ozarks.

A noted conservationist, Chuck Leavell is one of only three recipients of an Honorary Forest Ranger award from the U.S. Forest Service and is also a past recipient of the National Outstanding Tree Farmer award. Johnny Morris, is also a legend in conservation and is a recipient of the prestigious Audubon Medal, considered by many to be the highest award in conservation. In the 114-year history of Audubon there have been only 57 recipients for this prestigious award.

Awe-inspiring, nature-based entertainment venue.

The Rolling Stones concert at Thunder Ridge Nature Arena underscores Johnny’s commitment to create one of the finest outdoor entertainment venues in North America and shares the beauty of his beloved Ozarks with others for generations to come. It’s more than just a place for spectacular concerts, rodeos and conventions. The property has been placed in a not-for-profit foundation, and all proceeds from events at the arena will go to further enhance the facilities and support conservation.

Located on about 1,200 acres near Ridgedale, Thunder Ridge is adjacent to the Bass Pro Shops Big Cedar Lodge on land originally purchased by Johnny Morris about 30 years ago. For the past decade, it has accommodated large gatherings, including concerts by Garth Brooks, Hank Williams Jr., Chris Janson, Dierks Bentley, Tracy Lawrence and other major acts.

It also has hosted air shows, hot air balloon shows, the U.S. Open Bowfishing Championship, the U.S. Open National Bass Tournament, the National 4-H Youth Council, rodeos, conventions, symposiums and special events and is set to host nature-based activities for all ages and interests for years to come.

Thunder Ridge is the latest jewel in Big Cedar Lodge’s proud tradition of hosting world-class hospitality and entertainment experiences that span a variety of recreational markets.

The vision for the future is to continue to host a wide variety of world-class outdoor events. The Rolling Stones performance is only the latest in a summer full of marquee concerts already announced for Thunder Ridge. This lineup includes:

  • May 25 – Morgan Wallen
  • June 13 – Chris Stapleton
  • June 15 – Fuerza Regida
  • July 21 – The Rolling Stones
  • July 27 – Luke Bryan
  • Aug. 31 – Slightly Stoopid & Dirty Heads w / HIRIE
  • Sept. 8 – Imagine Dragons
  • Sept. 21 – Pitbull

More than six decades of rock-and-roll royalty.

Over the last 60 years, The Rolling Stones have defined the rock-and-roll movement, led by vocalist Mick Jagger and guitarist Keith Richards. The group has estimated album sales of 250 million, making them one of the best-selling musical artists of all time.

The Stones have released 30 studio albums, 23 live albums and 12 official compilation albums; and CNN has called them “far and away the most successful act in rock today.” The Grammy Award-winning band was inducted into the Rock & Roll Hall of Fame in 1989 and the U.K. Music Hall of Fame in 2004 and have been ranked by music-industry watchdogs Billboard magazine and Rolling Stone magazine as one of the greatest bands of all time.

This tour is in support of their widely heralded Hackney Diamonds album release from 2022, which received rave reviews from fans and music critics everywhere.

About Thunder Ridge Nature Arena

Thunder Ridge Nature Arena is a breathtaking outdoor amphitheater nestled in the heart of the Ozarks in Ridgedale, Missouri, just a few miles south of Branson. Situated on over 1,200 acres of land dedicated to conservation, the venue offers stunning views of Table Rock Lake and the Boston Mountains of Arkansas. Thunder Ridge Nature Arena is part of the Johnny Morris Conservation Foundation, dedicated to preserving and celebrating the natural beauty of the Ozarks. All venue proceeds go directly to conservation efforts to protect the land, wildlife and natural habitats of the Ozark region.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jim Yeager
breakwhitelight (for Thunder Ridge Nature Arena)
jim@breakwhitelight.com
818-264-6812

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 04:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye